Menu

Delivering next-generation cancer therapies targeting cell state

By identifying and targeting the dysregulated cell states of cancer, we aim to transform the treatment of solid tumors and hematological malignancies with the next generation of targeted cancer therapies.

Atlases to Map Cancer Cell States

We have combined a proprietary database of single cell genomic data with an AI-powered computational platform that allows us to compare healthy cell development to cancer cell development and map out the drivers of tumorigenesis.

A Diverse Team of Innovators

We have assembled a team with deep expertise in cancer biology, medicinal chemistry, and computational science who work closely with leading physician-scientists.

Patient
Centered

At the center of everything we do are the patients. As pioneers in cancer cell state drug development, we aim to offer patients longer, higher quality lives.

Our Team

Platform
Powered

Our AI platform, AURIGIN™, allows us to identify targets, model systems, and biomarkers for efficient discovery and development of targeted cancer therapies.

Our Science

Product
Driven

Our pipeline is a direct result of our AURIGIN™ platform. Using AURIGIN, we are advancing programs designed to address the critical unmet needs of patients with solid tumor cancers or hematologic malignancies.

Our Pipeline

An urgent unmet need

The initial indications of our flagship candidate are cancers with high mortality rates.

30,000+ per year

Small-cell lung cancer (SCLC)

SCLC has a poor outlook due to late diagnosis and speed of spread

7%
Overall 5-year survival rate

50,000+ per year

Neuroendocrine prostate cancer (NEPC)

NEPC has a poor outlook due to late diagnosis and lack of effective treatment.

14%
Overall 5-year survival rate

20,000+ per year

Acute Myeloid Leukemia (AML)

AML has a poor outlook due to late diagnosis and speed of spread

30%
Overall 5-year survival rate
SOURCES:
  1. US population incidence rates from American Cancer Society (2023)
  2. Cancer.org — Source
  3. Over 288K new cases of prostate cancer (PC) per year (Source - Cancer.org) and 0.5% to 2% of newly diagnosed PC are classified as NEPC (Source - NCBI)
  4. NCBI — Source
  5. Leukemia & Lymphoma Society — Source
  6. Leukemia & Lymphoma Society — Source

Focused Team.
One purpose.

We have fostered a culture that encourages our team to be curious, to think strategically and creatively, and to push the limits of science. We honor diversity and individuality, and are united by a single commitment to serve the patients and families who need new treatments.

Make an impact.

Search for open positions at Auron Therapeutics.

Join us

Recent News

See All News
February 8, 2024

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and treating disrupted cell states of cancer, today announced the nomination of its first development candidate, AUTX-703. Using its proprietary AURIGIN platform, Auron identified a key driver of tumor cell plasticity and discovered AUTX-703, a potent, selective, orally bioavailable small molecule degrader of that target. AUTX-703 is being developed for the treatment of patients with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).

Read more

Heading

Heading

Heading

Heading

Heading
Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
aspekta 200
aspekta 700
barlow 200